Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708429 · ClinicalTrials.gov registry record
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
A clinical trial of Lynch Syndrome and Hereditary Cancer Syndrome, sponsored by San Raffaele University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 5
- Study locations
NCT06708429: Recruiting study of Lynch Syndrome and Hereditary Cancer Syndrome, sponsored by San Raffaele University.
NCT06708429 is a study of Lynch Syndrome and Hereditary Cancer Syndrome that is actively recruiting participants, run by San Raffaele University. The registered enrollment target is 300 participants, below the 2,302-participant average among 21 other Lynch Syndrome trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06708429, a study of Lynch Syndrome and Hereditary Cancer Syndrome, is actively recruiting participants, sponsored by San Raffaele University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.
Primary Outcome
True positive rate: the probability of a positive test result, conditioned on the individual truly being positive
Conditions Studied
Interventions
- DIAGNOSTIC_TEST LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Study Locations (5)
California
- Beckman Research Institute at City of Hope - Monrovia
Lombardy
- Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital - Milan
MI
- Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori - Milan
PM
- Dipartimento di controllo qualità e rischio chimico biologico, AOOR Villa Sofia Cervello - Palermo
Other
- Chirurgia Generale, Azienda Ospedaliero Universitaria di Cagliari - Cagliari
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2034-06-01 |
What NCT06708429 shows while recruiting
NCT06708429 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,302-participant average among 21 other Lynch Syndrome trials with a reported enrollment target (87% lower).
The record links to 10 conditions, with Lynch Syndrome appearing as the primary indexed condition, and to 1 intervention - of which LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) is the first listed.
NCT06708429 lists 5 locations in 5 states (California, Lombardy, MI).
Frequently Asked Questions
What is clinical trial NCT06708429 about?
NCT06708429 is a clinical study titled "Lynch Syndrome X-Talk of Enteral Mucosa With Immune System". Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach...
What is the current status of trial NCT06708429?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-06-01. Estimated completion is 2034-06-01.
What conditions does trial NCT06708429 study?
This clinical trial studies the following conditions: Lynch Syndrome, Hereditary Cancer Syndrome, Hereditary Cancer, MLH1 Gene Mutation, HNPCC.
What interventions are being tested in trial NCT06708429?
The interventions under investigation include: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06708429?
This trial is sponsored by San Raffaele University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708429 being conducted?
This trial has 5 study locations across California, Lombardy, MI, PM. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lynch Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06708429's enrollment target sits among peer trials
300 13th of 21 higher than 9 of 21 other Lynch Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lynch Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
RECRUITING
-
Lynch Syndrome Integrative Epidemiology and Genetics
RECRUITING
-
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
RECRUITING · Phase 2
-
Identifying and Caring for Individuals With Inherited Cancer Syndrome
RECRUITING · NA
-
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI